Antiva Biosciences was founded by Karl Hostetler, M.D., with a core mission to develop innovative antiviral therapies. The company focuses on creating topical treatments for pre-cancerous cervical lesions and HPV infections, aiming to provide women with a first-in-class, self-administered therapy. Antiva's medicinal chemistry platform also targets other viruses, including HIV and herpes, addressing significant unmet medical needs in the biopharmaceutical market.
Notable figures associated with Antiva include its founder Karl Hostetler, M.D., a recognized expert in antiviral research. The company has attracted investment from leading biotech venture capital firms. Key achievements include the development of novel therapeutic candidates that offer a potential breakthrough in treating HPV-related conditions. Antiva's impact lies in its promise to empower women with effective, private treatment options, potentially transforming the landscape of antiviral therapy.
